These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 15567093)

  • 21. Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy.
    Weinberg A; Gona P; Nachman SA; Defechereux P; Yogev R; Hughes W; Wara D; Spector SA; Read J; Elgie C; Cooper M; Dankner W;
    J Infect Dis; 2006 Jan; 193(2):302-11. PubMed ID: 16362896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
    Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL
    HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody response to an eight-site intradermal rabies vaccination in patients infected with Human Immunodeficiency Virus.
    Sirikwin S; Likanonsakul S; Waradejwinyoo S; Pattamadilok S; Kumperasart S; Chaovavanich A; Manatsathit S; Malerczyk C; Wasi C
    Vaccine; 2009 Jul; 27(32):4350-4. PubMed ID: 19487057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.
    ; Arrivé E; Chaix ML; Nerrienet E; Blanche S; Rouzioux C; Coffie PA; Kruy Leang S; McIntyre J; Avit D; Srey VH; Gray G; N'Dri-Yoman T; Diallo A; Ekouévi DK; Dabis F
    AIDS; 2009 Apr; 23(7):825-33. PubMed ID: 19307941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry.
    Blish CA; Nedellec R; Mandaliya K; Mosier DE; Overbaugh J
    AIDS; 2007 Mar; 21(6):693-702. PubMed ID: 17413690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.
    Greco FA; Bonomi P; Crawford J; Kelly K; Oh Y; Halpern W; Lo L; Gallant G; Klein J
    Lung Cancer; 2008 Jul; 61(1):82-90. PubMed ID: 18255187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks.
    Paton NI; Aboulhab J
    HIV Med; 2005 Jan; 6(1):13-20. PubMed ID: 15670247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.
    Advani R; Forero-Torres A; Furman RR; Rosenblatt JD; Younes A; Ren H; Harrop K; Whiting N; Drachman JG
    J Clin Oncol; 2009 Sep; 27(26):4371-7. PubMed ID: 19636010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selection and characterization of an HIV-1 gp120-binding affibody ligand.
    Wikman M; Rowcliffe E; Friedman M; Henning P; Lindholm L; Olofsson S; Ståhl S
    Biotechnol Appl Biochem; 2006 Sep; 45(Pt 2):93-105. PubMed ID: 16712522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Investigation of anti-R7V antibodies in HIV-infected patients under highly active antiretroviral therapy].
    Ergünay K; Altinbaş A; Calik Başaran N; Unal S; Us D; Karabulut E; Ustaçelebi S
    Mikrobiyol Bul; 2008 Jul; 42(3):413-9. PubMed ID: 18822884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T-cell vaccination against anti-CD4 autoimmunity in HIV-1 infected patients.
    Abulafia-Lapid R; Bentwich Z; Keren-Zur Y; Cohen IR; Atlan H
    J Clin Virol; 2004 Dec; 31 Suppl 1():S48-54. PubMed ID: 15567094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiviral activity of low-dose alovudine in antiretroviral-experienced patients: results from a 4-week randomized, double-blind, placebo-controlled dose-ranging trial.
    Ghosn J; Quinson AM; Sabo N; Cotte L; Piketty C; Dorléacq N; Bravo ML; Mayers D; Harmenberg J; Mårdh G; Valdez H; Katlama C
    HIV Med; 2007 Apr; 8(3):142-7. PubMed ID: 17461857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Post infection antiidiotype vaccination against HIV: results of a phase Ia pilot study].
    Schedel I; Sutor GC; Jurkiewicz E; Hunsmann G; Lundin K; Hirn M
    Immun Infekt; 1993 Apr; 21 Suppl 1():49-51. PubMed ID: 8344693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis.
    Plevy S; Salzberg B; Van Assche G; Regueiro M; Hommes D; Sandborn W; Hanauer S; Targan S; Mayer L; Mahadevan U; Frankel M; Lowder J
    Gastroenterology; 2007 Nov; 133(5):1414-22. PubMed ID: 17920064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Affinity hemodialysis for antiviral therapy. II. Removal of HIV-1 viral proteins from cell culture supernatants and whole blood.
    Tullis RH; Duffin RP; Zech M; Ambrus JL
    Blood Purif; 2003; 21(1):58-63. PubMed ID: 12566663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Anti-carbohydrate monoclonal antibodies against human immunodeficiency virus].
    Nakasone T; Yamamoto S; Honda M; Horie R; Shigeta K; Saito T
    Nihon Rinsho; 1993 Sep; 51 Suppl():219-23. PubMed ID: 8271387
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.